Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
523 stopped studies mapped to Lymphoid Leukemia and descendants · 86% state a reason
Over the 523 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03733249 | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | Phase 1 / Phase 2 | terminated | Nov 7, 2018 | Bellicum Pharmaceuticals | not stated | Not stated |
| NCT03884972 | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or… | Phase 1 | withdrawn | Mar 21, 2019 | M.D. Anderson Cancer Center | Request by sponsor due to no enrollment of participants on study | Enrollment / accrual |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT05320380 | A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment… | Phase 1 / Phase 2 | withdrawn | Apr 11, 2022 | Children's Oncology Group | Withdrawn per CS0150757 | Other (stated, no rule matched) |
| NCT05519527 | STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL… | Phase 1 | withdrawn | Aug 29, 2022 | M.D. Anderson Cancer Center | 0 patient accrual | Enrollment / accrual |
| NCT04029038 | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or… | Phase 1 / Phase 2 | withdrawn | Jul 23, 2019 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT02134782 | Yoga Fatigue Study | N/A | terminated | May 9, 2014 | The Hospital for Sick Children | The study was closed early for poor accrual when 125/210 planned participants had been enrolled and… | Enrollment / accrual |
| NCT03229876 | Safety and Efficacy Evaluation of CD19-UCART | N/A | suspended | Jul 26, 2017 | Bioray Laboratories | Sponsor decision | Sponsor / business decision |
| NCT04016805 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants… | Phase 2 | terminated | Jul 11, 2019 | TG Therapeutics, Inc. | Strategic/Business decision | Sponsor / business decision |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Phase 1 | terminated | Dec 3, 2021 | Exelixis | Due to Sponsor reasons. | Other (stated, no rule matched) |
| NCT01013961 | Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic… | Phase 2 | terminated | Nov 16, 2009 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients… | Early Phase 1 | terminated | Sep 5, 2017 | Rutgers, The State University of New Jersey | Lack of enrollment | Enrollment / accrual |
| NCT02656303 | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib… | Phase 2 | terminated | Jan 14, 2016 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT02935543 | CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL | Phase 2 | terminated | Oct 17, 2016 | University of Pennsylvania | Study is terminated because of administrative reasons. | Other (stated, no rule matched) |
| NCT05037669 | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric… | Phase 1 | withdrawn | Sep 8, 2021 | University of Pennsylvania | No available investigational product | Other (stated, no rule matched) |
| NCT04149821 | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | Phase 2 | terminated | Nov 4, 2019 | Weill Medical College of Cornell University | Terminated due to low accrual | Enrollment / accrual |
| NCT05645133 | QPlus Pediatric Reference Interval | — | terminated | Dec 9, 2022 | HemoSonics LLC | PI relocated to another institution | Other (stated, no rule matched) |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid… | Phase 1 / Phase 2 | terminated | May 12, 2015 | Asana BioSciences | Business decision | Sponsor / business decision |
| NCT03705507 | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of…(SeluDex) | Phase 1 / Phase 2 | terminated | Oct 15, 2018 | University of Birmingham | Poor recruitment, due to a change in the standard of care for this patient population with the use… | Enrollment / accrual |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Phase 1 | terminated | Sep 26, 2016 | MEI Pharma, Inc. | discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT03043430 | Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients | Phase 4 | terminated | Feb 6, 2017 | Brooke Army Medical Center | Research manpower shortage | Other (stated, no rule matched) |
| NCT03919214 | Hypertension Management in Cancer Patients | N/A | terminated | Apr 18, 2019 | Duke University | Initially suspended due to Covid-19. After much consideration, it was determined that we do not… | COVID-19 / pandemic |
| NCT05361356 | Spectral CT Clinical Trial | N/A | terminated | May 4, 2022 | Philips (China) Investment CO., LTD | Investigational product had been released in NMPA, Sponsor decided to terminate the study aligned… | Investigator |
| NCT00558961 | Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic…(GL-CLB-001) | Phase 1 / Phase 2 | terminated | Nov 16, 2007 | Jewish General Hospital | Unsatisfactory enrollment | Enrollment / accrual |
| NCT04311866 | Femoral Pediatric Fractures. Walking Spica Cast vs Synthetic Pants | N/A | withdrawn | Mar 17, 2020 | Universidad Autonoma de Nuevo Leon | Lack of material for treatment of the patients | Other (stated, no rule matched) |
| NCT05209308 | Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL(CORAL) | Phase 2 | withdrawn | Jan 26, 2022 | MEI Pharma, Inc. | Discontinuation of zandelisib development | Other (stated, no rule matched) |
| NCT04156659 | Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or… | Phase 2 | withdrawn | Nov 7, 2019 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | Phase 1 | withdrawn | Aug 24, 2022 | Shanghai Pudong Hospital | The study is not initiated and we want it to be withdrawn. | Other (stated, no rule matched) |
| NCT03370185 | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic…(BRIO) | Phase 2 | withdrawn | Dec 12, 2017 | SecuraBio | Reassessing corporate priorities. | Other (stated, no rule matched) |
| NCT02292225 | Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi… | Phase 1 | terminated | Nov 17, 2014 | SecuraBio | The scope of the program has been reduced to focus resources on studies which can potentially… | Other (stated, no rule matched) |
| NCT00589316 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body… | Phase 1 | terminated | Jan 9, 2008 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT04095858 | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease…(CATHY) | Phase 3 | terminated | Sep 19, 2019 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business Reasons | Sponsor / business decision |
| NCT04225676 | Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young… | Phase 2 | terminated | Jan 13, 2020 | Novartis Pharmaceuticals | Terminated due to slow enrollment | Enrollment / accrual |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT05168748 | CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia | Phase 1 | withdrawn | Dec 23, 2021 | Novartis Pharmaceuticals | Sponsor's decision | Sponsor / business decision |
| NCT04343027 | Patient Satisfaction in the Orthopedic Surgery Clinic | N/A | withdrawn | Apr 13, 2020 | NYU Langone Health | Withdrawn project - did not progress to enrollment. | Enrollment / accrual |
| NCT05570188 | Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic… | Phase 1 / Phase 2 | withdrawn | Oct 6, 2022 | Kunming Hope of Health Hospital | The PI decides to stop. | Other (stated, no rule matched) |
| NCT05571540 | Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | Phase 1 / Phase 2 | withdrawn | Oct 7, 2022 | Kunming Hope of Health Hospital | The PI decides to stop. | Other (stated, no rule matched) |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and… | Early Phase 1 | withdrawn | Apr 27, 2021 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | No proper participant is found. | Other (stated, no rule matched) |
| NCT04595851 | Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer… | N/A | terminated | Oct 22, 2020 | University of Michigan Rogel Cancer Center | accrual difficulties | Enrollment / accrual |
| NCT05611086 | N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia | Phase 4 | terminated | Nov 9, 2022 | Teny Tjitra Sari | The study stopped because the study period already ended | Other (stated, no rule matched) |
| NCT03518112 | Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia… | Phase 2 | terminated | May 8, 2018 | M.D. Anderson Cancer Center | Due to Competing Studies | Other (stated, no rule matched) |
| NCT02811783 | Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of… | Phase 3 | terminated | Jun 23, 2016 | Elorac, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04655261 | Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection…(FIRST) | — | terminated | Dec 7, 2020 | AbbVie | Lack of Recruitment | Enrollment / accrual |
| NCT04504708 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant… | Phase 1 / Phase 2 | terminated | Aug 7, 2020 | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | Study terminated early due to business decision. | Sponsor / business decision |
| NCT02618109 | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute…(LABMI) | Phase 4 | terminated | Dec 1, 2015 | University Hospital, Angers | recruitment difficulties | Enrollment / accrual |
| NCT02225275 | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic… | Phase 2 | terminated | Aug 26, 2014 | M.D. Anderson Cancer Center | Due to slow accrual | Enrollment / accrual |
| NCT04282174 | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies(2019-KOE-001) | Phase 2 | withdrawn | Feb 24, 2020 | Baptist Health South Florida | Study was split into two new studies before the first participant was enrolled. | Enrollment / accrual |
| NCT01440179 | SAR3419 in Acute Lymphoblastic Leukemia(MYRALL) | Phase 2 | terminated | Sep 26, 2011 | Sanofi | The study is stopped due to very modest activity compared to competitors | Other (stated, no rule matched) |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 26, 2023source: clinicaltrials